Abbott, a global healthcare leader, has reported its financial results for the third quarter of 2025, showcasing significant growth in sales and earnings per share. The company's third-quarter reported sales increased by 6.9 percent, with organic sales growing by 5.5 percent. Excluding COVID-19 testing-related sales, organic sales grew by an impressive 7.5 percent.
In terms of earnings per share, Abbott reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30 for the third quarter. The reported operating margin was 18.1 percent of sales, while the adjusted operating margin stood at 23.0 percent, reflecting a 40 basis point increase.
Looking at the performance across different segments, the nutrition business saw a 4.2 percent increase in sales on a reported basis and a 4.0 percent increase on an organic basis in the third quarter. This growth was primarily driven by strong performance in the adult nutrition category, particularly with products like Ensure and Glucerna.
In the diagnostics segment, global sales decreased by 6.6 percent on a reported basis and 7.8 percent on an organic basis. However, when excluding COVID-19 testing-related sales, there was a 0.4 percent increase in organic sales. The challenging market conditions in China impacted the segment's growth during the quarter.
Established pharmaceuticals reported a 7.5 percent increase in sales on a reported basis and a 7.1 percent increase on an organic basis in the third quarter, with key emerging markets driving the growth.
Meanwhile, the medical devices segment witnessed a robust 14.8 percent increase in sales on a reported basis and a 12.5 percent increase on an organic basis. The double-digit growth was primarily fueled by strong performance in areas such as diabetes care, rhythm management, and heart failure.
Abbott reaffirmed its full-year 2025 organic sales growth guidance and adjusted diluted EPS guidance range. The company continues to demonstrate its commitment to delivering value to shareholders, as evidenced by its declaration of a quarterly dividend, marking the 407th consecutive quarterly dividend declared.
This strong financial performance underscores Abbott's position as a leader in the global healthcare industry, with a diverse portfolio of life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines. The market has reacted to these announcements by moving the company's shares 1.44% to a price of $133.27. For more information, read the company's full 8-K submission here.
